All In Biotech

Drug Trial Radar · NCT07011511

Single Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of LAI MMV055 Alone and in Combination With MMV371 in Healthy Participants

A First-in-Human, Single-Centre, Single Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of Intramuscular Injection(s) of Long-Acting Injectable Formulations of MMV055 Alone (Part A) and in Combination With MMV371 (Part B) in Healthy Participants

Last checked: Nov 20, 2026Latest source record: Jun 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

72

Planned (sponsor's estimate)

Start

Jun 30, 2025

Primary completion

Dec 2, 2027

Study completion Dec 2, 2027

Sponsor

Lead sponsor
Medicines for Malaria VentureAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Quotient Sciences; The Doctors Laboratory Ltd
First posted
Jun 8, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Double (participant, investigator)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 60 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a single-centre, participant- and investigator-blind, randomised, placebo controlled, single ascending dose study to assess the safety, tolerability and PK of a single dose of IM depot injection(s) of LAI formulations of MMV055 administered alone (Part A) and in combination with MMV371 (Part B) in healthy participants. It is planned to enroll up to 6 sequential cohorts of 8 healthy male participants and healthy female participants of non-childbearing potential in Part A. In Part B, up to 3 sequential cohorts of 8 healthy male participants and healthy non-pregnant, non-lactating female participants will be enrolled. In each cohort, participants will be randomised in a ratio of 6 active investigational medicinal product (IMP) to 2 placebo. Part A of the study will include two components, Parts A1 and A2. Part A1 includes two initial cohorts, with planned doses of 40 and 100mg, respectively. It is intended to document the human elimination T1/2 of MMV055, which will then be used to shorten the proposed End of Study (EOS) of 48 weeks, if possible. All cohorts will follow a sentinel dosing design. On Day 1, two sentinel participants (sentinel group) will be randomly assigned to receive a single IM dose of either active IMP or placebo (1 participant each) to assess safety and tolerability (including ISRs). The sentinel group will be dosed concomitantly at least 7 days prior to the rest of the cohort (main group). The main group will comprise 6 participants randomly assigned to receive a single IM dose of either active IMP or placebo in a 5:1 ratio to assess safety and tolerability (including ISRs).

Conditions

  • Malaria, Falciparum

Interventions

  • MMV055 Dose 1Drug

    40mg

  • MMV055 Dose 2Drug

    100mg

  • MMV055 Dose 3Drug

    200mg

  • MMV055 Dose 4Drug

    400mg

  • MMV055 Dose 5Drug

    800mg

  • MMV055 Dose 6Drug

    TBCmg

  • Matching placebo Part ADrug

    Part A

  • Matching placebo Part BDrug

    Part B

  • MMV055/MMV371 Combo 1Combination product

    Combination 1

  • MMV055/MM371 Combo 2Combination product

    Combination 2

  • MMV055/MMV371 Combo 3Combination product

    Combination 3

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety - Incidence of AEsTime frame: From enrollment to the last follow up visit at week 56
  2. Safety - Incidence of Injection Site ReactionsTime frame: From enrollment to the last follow up visit at week 56
  3. Safety - Incidence of physical examination findingsTime frame: From enrollment to the last follow up visit at week 56
  4. Safety - Vital signs changes from baselineTime frame: From enrollment to the last follow up visit at week 56
  5. Safety - ECG changes from baseline, QT intervalsTime frame: From enrollment to the last follow up visit at week 56
  6. Safety - ECG changes from baseline, PR and QRS intervalsTime frame: From enrollment to the last follow up visit at week 56
  7. Part 1 only: plasma concentrations of MMV055: CmaxTime frame: From enrollment to the last follow up visit at week 56
  8. Part 1 only: plasma concentrations of MMV055: AUC(0-last)Time frame: From enrollment to the last follow up visit at week 56
  9. Part 1 only: plasma concentrations of MMV055: AUC(0-inf)Time frame: From enrollment to the last follow up visit at week 56
  10. Part 1 only: plasma concentrations of MMV055: T1/2Time frame: From enrollment to the last follow up visit at week 56

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Quotient Sciences

    Nottingham, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.